- References (2)
Product nameDoxorubicin hydrochloride, Topoisomerase II inhibitor
DescriptionTopoisomerase II inhibitor. Antibiotic with cytotoxic actions.
Topoisomerase II inhibitor (IC50 = 100 nM, Hep3B cells). DNA intercalator that prevents synthesis of nucleic acid. Induces apoptosis.
Chemical name(8S,10S)-10-[(3-Amino-2,3,6-trideoxy-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 25 mM and in water to 50 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
All lanes : Anti-DR5 antibody [EPR22276] (ab230969) at 1/1000 dilution
Lane 1 : Untreated HCT116 (human colorectal carcinoma epithelial cell), whole cell lysate
Lane 2 : HCT116 treated with 0.5 µM doxorubicin (ab120629) for 24 hours, whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Exposure time: 3 minutes
The molecular weight observed is consistent with what has been described in the literature, the 40kDa band is a cleaved form (PMID: 20515924, 16297203).
Blocking/Dilution buffer: 5% NFDM/TBST.
This product has been referenced in:
- Sauter KA et al. Doxorubicin and daunorubicin induce processing and release of interleukin-1ß through activation of the NLRP3 inflammasome. Cancer Biol Ther 11:1008-16 (2011). Read more (PubMed: 21464611) »
- Lal S et al. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 11:115-28 (2010). Read more (PubMed: 20302569) »
- Gieseler F et al. Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Ann Hematol 69 Suppl 1:S13-7 (1994). Read more (PubMed: 8061108) »